|Articles|August 2, 2004

In the Spotlight August 2004

Pharmaceutical science and technology innovations

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance. Subscribe to Pharmaceutical Technology and never miss an industry breakthrough.

Subscribe

Related Content

Genglycos (pariglasgene brecaparvovec-opnr), a gene therapy for adult and pediatric patients eight years and older with glycogen storage disease type Ia recieved accelerated approval from the FDA.

GSDIa Gene Therapy Approval Signals New Path for Rare Disease Manufacturing

ByZachary Zubulake

August 20th 2026

Glowing neural network inside a transparent antibiotic capsule surrounded by a large language model on a black background. Illustration of the concept of AI assistance in pharmacy and drug discovery | Image Credit: ©Dragon Claws -stock.adobe.com

How AI Can Assist with Post-Marketing Changes

ByBeena Wood

August 19th 2026

Q&A: Why Sponsors Are Turning to Mixed FSP/FSO Models

BySamantha Hadfield

August 19th 2026

How China's biotech surge is reshaping US drug licensing, manufacturing control, and FDA data trust, the key shifts pharma professionals must track.

PharmTech Explained: China's Biotech Rise Signals New Risks for US Manufacturers

ByZachary Zubulake,Saharsh Davuluri,John Stanford

August 18th 2026

Green gelatin capsule resting on a translucent amber liquid drop, isolated on transparent background | Image Credit: ©Nina -stock.adobe.com

A Capsule-in-Capsule Platform for Multi-Phase Release of Liquid and Solid Formulations

ByUsha Chowdhury ,Jyothi Gautam,Erin Burke

August 17th 2026

In the Spotlight August 2004

Related Content

GSDIa Gene Therapy Approval Signals New Path for Rare Disease Manufacturing

How AI Can Assist with Post-Marketing Changes

Q&A: Why Sponsors Are Turning to Mixed FSP/FSO Models

PharmTech Explained: China's Biotech Rise Signals New Risks for US Manufacturers

A Capsule-in-Capsule Platform for Multi-Phase Release of Liquid and Solid Formulations

Trending on Pharmaceutical Technology

GSDIa Gene Therapy Approval Signals New Path for Rare Disease Manufacturing

Ask the Expert: Complying with Standards

How the Nitrosamine Guidance Shift is Changing LC-MS Workflows for APIs and Peptides

Q&A: Why Sponsors Are Turning to Mixed FSP/FSO Models

What Does Overton's FDA Nomination Mean for Drug Reviews?